Engineering the Extraordinary in Global Healthcare
Founded in 1949 by Earl Bakken and Palmer Hermundslie, Medtronic began as a small medical equipment repair shop in Minneapolis. Today, it stands as the world’s largest medical device company, headquartered in Dublin, Ireland, with operational headquarters in Minneapolis, Minnesota. Employing over 95,000 individuals across more than 150 countries, Medtronic’s mission is to alleviate pain, restore health, and extend life for millions worldwide.
Medtronic’s expansive portfolio addresses over 70 health conditions, including Parkinson’s disease, diabetes, cardiovascular diseases, and spinal disorders. Notably, the company has pioneered innovations such as the MiniMed™ 780G insulin pump system and the BrainSense™ Adaptive deep brain stimulation device, enhancing personalized care for patients.
In its fiscal year 2025 second quarter, Medtronic reported worldwide revenue of $8.403 billion, marking a 5.3% increase. This growth underscores the company’s robust performance across its cardiovascular, medical-surgical, neuroscience, and diabetes segments.
Medtronic continues to invest in research and development, with over 191 active clinical trials, aiming to bring cutting-edge solutions to market. The company’s commitment to innovation is further exemplified by its recent FDA approval for the Simplera Sync™ sensor, enhancing diabetes management for patients using the MiniMed™ 780G system.
Beyond technological advancements, Medtronic emphasizes healthcare equity and community engagement. Its 2024 Impact Report highlights initiatives like the Healthy Neighbor program, aiming to improve health outcomes in underserved communities.
As Medtronic continues to lead in medical technology, its dedication to transforming lives through innovative solutions remains unwavering, solidifying its position at the forefront of global healthcare.
